Identification of genetic variants in the human indoleamine 2,3-dioxygenase (IDO1) gene, which have altered enzyme activity

Million Arefayene, Santosh Philips, Donghua Cao, Sudharani Mamidipalli, Zeruesenay Desta, David A. Flockhart, David S. Wilkes, Todd Skaar

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

OBJECTIVES: Indoleamine 2,3-dioxygenase (IDO), a rate-limiting enzyme in tryptophan catabolism, is a key regulator of immune tolerance. We identified genetic variations in the IDO1 gene and evaluated their functional activities using in-vitro transfection studies. METHODS: We resequenced the exons and the intron/exon borders of the IDO1 gene in 96 samples from the Coriell DNA Repository. To determine the functional effects of the coding variations that were predicted to have functional consequences, we expressed three of the variant cDNAs in COS-7 and HEK293 cells and determined their enzyme activity. RESULTS: Seventeen variants were identified; three were nonsynonymous single nucleotide polymorphisms (AlaThr, ArgHis, LeuIle) and one was a 9bp deletion in exon 7. Compared with the wild-type protein, the Arg77His and the 9bp deletion resulted in significantly reduced protein expression and in nearly complete loss of enzyme activity. The allelic frequencies of these two functional variants were approximately 1% and were exclusively observed in the African-American samples. CONCLUSION: We conclude that there are naturally occurring polymorphisms that render the human IDO1 gene nonfunctional and should result in reduced IDO activity in affected individuals.

Original languageEnglish
Pages (from-to)464-476
Number of pages13
JournalPharmacogenetics and Genomics
Volume19
Issue number6
DOIs
StatePublished - Jun 1 2009

Fingerprint

Indoleamine-Pyrrole 2,3,-Dioxygenase
Exons
Enzymes
Genes
Immune Tolerance
HEK293 Cells
COS Cells
Tryptophan
African Americans
Introns
Single Nucleotide Polymorphism
Transfection
Proteins
Complementary DNA
DNA

Keywords

  • 2,3-dioxygenase
  • Functional genomics
  • Genetic variants
  • Immune tolerance
  • Indoleamine
  • Kynurenine
  • Tryptophan

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Molecular Medicine
  • Genetics(clinical)

Cite this

Identification of genetic variants in the human indoleamine 2,3-dioxygenase (IDO1) gene, which have altered enzyme activity. / Arefayene, Million; Philips, Santosh; Cao, Donghua; Mamidipalli, Sudharani; Desta, Zeruesenay; Flockhart, David A.; Wilkes, David S.; Skaar, Todd.

In: Pharmacogenetics and Genomics, Vol. 19, No. 6, 01.06.2009, p. 464-476.

Research output: Contribution to journalArticle

Arefayene, Million ; Philips, Santosh ; Cao, Donghua ; Mamidipalli, Sudharani ; Desta, Zeruesenay ; Flockhart, David A. ; Wilkes, David S. ; Skaar, Todd. / Identification of genetic variants in the human indoleamine 2,3-dioxygenase (IDO1) gene, which have altered enzyme activity. In: Pharmacogenetics and Genomics. 2009 ; Vol. 19, No. 6. pp. 464-476.
@article{51b9d4f6964b449a94b32d7a2dba7d4e,
title = "Identification of genetic variants in the human indoleamine 2,3-dioxygenase (IDO1) gene, which have altered enzyme activity",
abstract = "OBJECTIVES: Indoleamine 2,3-dioxygenase (IDO), a rate-limiting enzyme in tryptophan catabolism, is a key regulator of immune tolerance. We identified genetic variations in the IDO1 gene and evaluated their functional activities using in-vitro transfection studies. METHODS: We resequenced the exons and the intron/exon borders of the IDO1 gene in 96 samples from the Coriell DNA Repository. To determine the functional effects of the coding variations that were predicted to have functional consequences, we expressed three of the variant cDNAs in COS-7 and HEK293 cells and determined their enzyme activity. RESULTS: Seventeen variants were identified; three were nonsynonymous single nucleotide polymorphisms (AlaThr, ArgHis, LeuIle) and one was a 9bp deletion in exon 7. Compared with the wild-type protein, the Arg77His and the 9bp deletion resulted in significantly reduced protein expression and in nearly complete loss of enzyme activity. The allelic frequencies of these two functional variants were approximately 1{\%} and were exclusively observed in the African-American samples. CONCLUSION: We conclude that there are naturally occurring polymorphisms that render the human IDO1 gene nonfunctional and should result in reduced IDO activity in affected individuals.",
keywords = "2,3-dioxygenase, Functional genomics, Genetic variants, Immune tolerance, Indoleamine, Kynurenine, Tryptophan",
author = "Million Arefayene and Santosh Philips and Donghua Cao and Sudharani Mamidipalli and Zeruesenay Desta and Flockhart, {David A.} and Wilkes, {David S.} and Todd Skaar",
year = "2009",
month = "6",
day = "1",
doi = "10.1097/FPC.0b013e32832c005a",
language = "English",
volume = "19",
pages = "464--476",
journal = "Pharmacogenetics and Genomics",
issn = "1744-6872",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Identification of genetic variants in the human indoleamine 2,3-dioxygenase (IDO1) gene, which have altered enzyme activity

AU - Arefayene, Million

AU - Philips, Santosh

AU - Cao, Donghua

AU - Mamidipalli, Sudharani

AU - Desta, Zeruesenay

AU - Flockhart, David A.

AU - Wilkes, David S.

AU - Skaar, Todd

PY - 2009/6/1

Y1 - 2009/6/1

N2 - OBJECTIVES: Indoleamine 2,3-dioxygenase (IDO), a rate-limiting enzyme in tryptophan catabolism, is a key regulator of immune tolerance. We identified genetic variations in the IDO1 gene and evaluated their functional activities using in-vitro transfection studies. METHODS: We resequenced the exons and the intron/exon borders of the IDO1 gene in 96 samples from the Coriell DNA Repository. To determine the functional effects of the coding variations that were predicted to have functional consequences, we expressed three of the variant cDNAs in COS-7 and HEK293 cells and determined their enzyme activity. RESULTS: Seventeen variants were identified; three were nonsynonymous single nucleotide polymorphisms (AlaThr, ArgHis, LeuIle) and one was a 9bp deletion in exon 7. Compared with the wild-type protein, the Arg77His and the 9bp deletion resulted in significantly reduced protein expression and in nearly complete loss of enzyme activity. The allelic frequencies of these two functional variants were approximately 1% and were exclusively observed in the African-American samples. CONCLUSION: We conclude that there are naturally occurring polymorphisms that render the human IDO1 gene nonfunctional and should result in reduced IDO activity in affected individuals.

AB - OBJECTIVES: Indoleamine 2,3-dioxygenase (IDO), a rate-limiting enzyme in tryptophan catabolism, is a key regulator of immune tolerance. We identified genetic variations in the IDO1 gene and evaluated their functional activities using in-vitro transfection studies. METHODS: We resequenced the exons and the intron/exon borders of the IDO1 gene in 96 samples from the Coriell DNA Repository. To determine the functional effects of the coding variations that were predicted to have functional consequences, we expressed three of the variant cDNAs in COS-7 and HEK293 cells and determined their enzyme activity. RESULTS: Seventeen variants were identified; three were nonsynonymous single nucleotide polymorphisms (AlaThr, ArgHis, LeuIle) and one was a 9bp deletion in exon 7. Compared with the wild-type protein, the Arg77His and the 9bp deletion resulted in significantly reduced protein expression and in nearly complete loss of enzyme activity. The allelic frequencies of these two functional variants were approximately 1% and were exclusively observed in the African-American samples. CONCLUSION: We conclude that there are naturally occurring polymorphisms that render the human IDO1 gene nonfunctional and should result in reduced IDO activity in affected individuals.

KW - 2,3-dioxygenase

KW - Functional genomics

KW - Genetic variants

KW - Immune tolerance

KW - Indoleamine

KW - Kynurenine

KW - Tryptophan

UR - http://www.scopus.com/inward/record.url?scp=70149116670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70149116670&partnerID=8YFLogxK

U2 - 10.1097/FPC.0b013e32832c005a

DO - 10.1097/FPC.0b013e32832c005a

M3 - Article

C2 - 19514129

AN - SCOPUS:70149116670

VL - 19

SP - 464

EP - 476

JO - Pharmacogenetics and Genomics

JF - Pharmacogenetics and Genomics

SN - 1744-6872

IS - 6

ER -